- Home
- ANL vs IPSC Comparison
ANL vs IPSC Comparison
Compare ANL & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANL
- IPSC
- Stock Information
- Founded
- ANL 2004
- IPSC 2019
- Country
- ANL Cayman Islands
- IPSC United States
- Employees
- ANL N/A
- IPSC N/A
- Industry
- ANL
- IPSC Medicinal Chemicals and Botanical Products
- Sector
- ANL
- IPSC Health Care
- Exchange
- ANL Nasdaq
- IPSC Nasdaq
- Market Cap
- ANL 56.0M
- IPSC 49.6M
- IPO Year
- ANL 2023
- IPSC 2021
- Fundamental
- Price
- ANL $1.55
- IPSC $0.60
- Analyst Decision
- ANL Hold
- IPSC Strong Buy
- Analyst Count
- ANL 1
- IPSC 5
- Target Price
- ANL N/A
- IPSC $3.33
- AVG Volume (30 Days)
- ANL 7.4K
- IPSC 1.0M
- Earning Date
- ANL 08-08-2025
- IPSC 08-07-2025
- Dividend Yield
- ANL N/A
- IPSC N/A
- EPS Growth
- ANL N/A
- IPSC N/A
- EPS
- ANL N/A
- IPSC N/A
- Revenue
- ANL N/A
- IPSC $114,898,000.00
- Revenue This Year
- ANL N/A
- IPSC $1,064.82
- Revenue Next Year
- ANL N/A
- IPSC N/A
- P/E Ratio
- ANL N/A
- IPSC N/A
- Revenue Growth
- ANL N/A
- IPSC 8286.72
- 52 Week Low
- ANL $1.10
- IPSC $0.34
- 52 Week High
- ANL $4.10
- IPSC $3.29
- Technical
- Relative Strength Index (RSI)
- ANL 47.53
- IPSC 55.47
- Support Level
- ANL $1.50
- IPSC $0.52
- Resistance Level
- ANL $1.60
- IPSC $0.57
- Average True Range (ATR)
- ANL 0.07
- IPSC 0.04
- MACD
- ANL 0.02
- IPSC 0.00
- Stochastic Oscillator
- ANL 60.42
- IPSC 66.10
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.
About IPSC Century Therapeutics Inc.
Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.